Ardelyx (ARDX) Azione Prezzo
Ardelyx Prezzo
Negli ultimi 13 anni Ardelyx ha aumentato il fatturato del 39,4% all'anno, raggiungendo 407,32 Mio. USD. Per Ardelyx, il margine netto del -15,1% risulta in aumento rispetto al -1566,5% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Ardelyx è 11,22 USD, circa il 270,3% sopra il prezzo attuale di mercato. Su 17 analisti, 15 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Ardelyx Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Ardelyx Azione e analisi azionaria
Domande frequenti sull'azione Ardelyx
The business model of Ardelyx Inc revolves around developing and commercializing innovative therapeutics for patients with cardio-renal and gastrointestinal diseases. Ardelyx focuses on discovering and developing small molecule therapeutics that address unmet medical needs. The company's approach involves designing drugs that selectively modulate key molecules involved in specific disease processes. By targeting these molecules, Ardelyx aims to develop treatments that improve patients' quality of life and clinical outcomes. Ardelyx Inc strategically collaborates with partners to advance its pipeline and bring novel therapies to market, aiming to make a positive impact on patients' lives.
Ardelyx Inc is primarily active in the pharmaceutical industry.
The main competitors of Ardelyx Inc in the market include pharmaceutical companies such as Ardelyx Pharmaceuticals Inc, AstraZeneca plc, Bayer AG, Johnson & Johnson, Pfizer Inc, and GlaxoSmithKline plc. These companies also operate in the pharmaceutical industry and may offer similar products or target a similar customer base.
Ardelyx Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative therapeutic solutions for cardio-renal diseases. Established in 2007, Ardelyx has consistently worked towards addressing unmet medical needs through its proprietary drug discovery platform. The company focuses on designing small molecule therapeutics to target biological pathways involved in the treatment of conditions like hyperkalemia, IBS-C, and CKD. Ardelyx has successfully advanced its candidates through clinical trials, demonstrating their potential efficacy and safety. With a strong commitment to improving patient outcomes, Ardelyx continues to make significant strides in the field of biopharmaceuticals.
Ardelyx Inc has achieved several significant milestones in its journey. The company received FDA approval for its first product, a potassium binder called KAYEXALATE(R). This milestone marks a major breakthrough in addressing hyperkalemia, a condition characterized by high levels of potassium in the blood. Furthermore, Ardelyx advanced its research pipeline to develop innovative therapeutics for cardiorenal diseases and gastrointestinal disorders. The company also attained positive Phase 3 results for tenapanor, an investigational treatment for irritable bowel syndrome with constipation and hyperphosphatemia. With these achievements, Ardelyx Inc has positioned itself as a leading player in the healthcare industry.
Ardelyx Inc is primarily present in the United States, focusing on the development and commercialization of innovative medicines.
Ardelyx Inc represents a strong commitment to improving patient lives through innovative solutions. The company's corporate philosophy revolves around scientific excellence, collaboration, and a patient-centric approach. Ardelyx's values emphasize the pursuit of innovation, integrity, and quality in delivering transformative therapies. With a focus on developing novel treatment options for people with kidney and cardiovascular diseases, Ardelyx aims to address significant unmet medical needs. By combining dedicated research efforts, strategic partnerships, and a patient-centered mindset, Ardelyx Inc strives to create a positive impact and provide effective solutions in the healthcare industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 11,93 USD per l’azione Ardelyx (mediana: 11,22 USD), pari a +293,9 % rispetto all’ultimo prezzo. Il consenso si basa su 17 giudizi di analisti.
17 analisti valutano attualmente l’azione Ardelyx: 16 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Ardelyx ricavi pari a 487,14 Mio. USD e un utile per azione di -0,18 USD.
Convertita al tasso di cambio attuale, l’azione Ardelyx quota 2,72 EUR (3,03 USD).
L’azione Ardelyx (ARDX) è quotata su 5 borse, tra cui: NASDAQ (ARDX), SIX (Zürich) (41X.SW), Frankfurt (41X.F), München (41X.MU), Düsseldorf (41X.DU).
Ardelyx Inc. is a biopharmaceutical company based in the United States that focuses on developing medical solutions for the treatment of kidney and gastrointestinal diseases. The company was founded in 2007 and is headquartered in Fremont, California. Ardelyx has three main business areas: kidneys, gastrointestinal tract, and cardiology. Within these areas, the company focuses on developing innovative drugs based on the effects of intestinal hormones. The company's main focus is on the treatment of hyperphosphatemia, a kidney disease characterized by high levels of phosphate in the blood. Ardelyx has developed a drug called Tenapanor, which has shown promising results in clinical studies for reducing phosphate levels in the blood. The company also focuses on treating gastrointestinal diseases such as irritable bowel syndrome and chronic kidney failure. Ardelyx has an extensive portfolio of patents and intellectual property and has numerous partnerships with other pharmaceutical and biotechnology companies to reduce development costs and accelerate research activities. The company has received significant investments from venture capital firms and other financial investors in recent years. Ardelyx went public in 2014 and raised approximately $60 million. The company's business model is based on developing innovative medical solutions based on the research of intestinal hormones, with partnerships being an important component to leverage resources and expertise. Ardelyx aims to expand its research and development activities and expand its product pipeline by collaborating with other companies and leveraging synergies through partnerships. Overall, Ardelyx is a promising company in the field of biopharmaceutical research and development. With a broad portfolio of patents and intellectual property and a focus on researching new drugs and therapy approaches, Ardelyx has the potential to become a key player in drug development in the future.
Il attesa fatturato di Ardelyx ammonta a 487,14 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Ardelyx ammonta a -43,19 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Ardelyx è attualmente -17,09. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Ardelyx.
Il rapporto prezzo/fatturato (P/S) di Ardelyx è attualmente 1,52. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Ardelyx.
Il Quality Score AlleAktien per Ardelyx è 5/10.
L'ISIN di Ardelyx è US0396971071. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Ardelyx è A116X0. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Ardelyx è ARDX. Con questo simbolo di borsa vengono negoziate le azioni Ardelyx in borsa.
Azione Ardelyx
Gruppo di pari di Ardelyx
Ardelyx Ticker
Ardelyx FIGI
Altre metriche e analisi di Ardelyx in Deep Dive.
La nostra analisi azionaria dell'azione Ardelyx include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Ardelyx. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: